TA
TXG icon

Tactive Advisors’s 10x Genomics TXG Stock Holding History

Tactive Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-12,495
Closed -$479K – 330
2026
Q2 		$479K Buy
+12,495
New +$327K 0.12% 157

Other funds holding TXG

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
TWM
TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.66B AUM 22.28% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
RPWA
Regent Peak Wealth Advisors Atlanta, Georgia $577M AUM 20.1% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

Tactive Advisors's TXG Position: Q3 2026 in Review

Tactive Advisors sold out of 10x Genomics (TXG) in Q3 2026, closing a stake of 12,495 shares — an estimated $479K sold.

Tactive Advisors first reported a position in TXG in Q2 2026 and held it in 1 quarter. The position peaked at $479K in Q2 2026. 22 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Tactive Advisors reported no remaining 10x Genomics position as of Q3 2026 after selling out during the quarter.
  • Tactive Advisors sold 12,495 10x Genomics shares in Q3 2026, an estimated $479K.
  • Tactive Advisors first reported a position in 10x Genomics in Q2 2026 and held it in 1 quarter.
  • Tactive Advisors's 10x Genomics position peaked at $479K in Q2 2026.
  • 22 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Tactive Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.